Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Signs Up Another Oral Insulin Partner, Hedging Its Bets

This article was originally published in The Pink Sheet Daily

Executive Summary

Novo Nordisk places another oral insulin technology bet with Emisphere; expands partnership with Merrion beyond insulin.

You may also be interested in...



Looking For The New Lantus: Next-Gen Diabetes Hopefuls Defy Risks

The diabetes market presents competitive, commercial, and regulatory challenges, but its size and breadth spur emerging biotechs to develop an ever-wider range of treatments and technologies.

Novo Nordisk Looks Ahead After Tresiba Setback, Bets Against Biosimilars

The Danish pharma is focused on the latest formulation technology for insulin and GLP-1 and combinations thereof to sustain its diabetes market leader position. It’s not particularly worried about biosimilars, despite two of its top sellers coming off-patent in the next few years.

For Some, Oral Insulin’s Allure Persists Despite Hurdles

The recent release of preliminary Phase III results for Generex Biotechnology Corp.’s buccal spray Oral-lyn put the challenging, but alluring for a few dogged developers, oral insulin development space back in the spotlight momentarily.

Related Content

Topics

UsernamePublicRestriction

Register

PS071652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel